---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-25-000057"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:38:10.838221+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte appoints Dr. Olivier Brandicourt to board of directors

## Summary
- Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.
- Board determined Dr. Brandicourt qualifies as independent under Nasdaq rules.
- Receives initial equity award of $800,000 in nonstatutory stock options vesting over 36 months.
- Annual cash retainer of $50,000 and annual equity award of $450,000 (75% option, 25% RSU).
- Standard indemnification agreement entered; no reportable transactions per Item 404(a).

## SEC filing metadata
- accession: 0001649094-25-000057
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/0001649094-25-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/pcvx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-25-000057
- JSON: https://secwatch.observer/filing/0001649094-25-000057.json
- Plain text: https://secwatch.observer/filing/0001649094-25-000057.txt

## Key facts
- Executive change
  Dr. Olivier Brandicourt was appointed as Director at Vaxcyte, Inc..
  - Action: appointed
  - Role: Director
  source text: On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/0001649094-25-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.